NOT KNOWN FACTUAL STATEMENTS ABOUT AGO TUMOR

Hormonal therapy stays the treatment of first option for metastatic sufferers with endocrine-responsive breast cancer (LoE 1a A, In the past ++). The sequential use from the obtainable medicines is determined by the person pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at enough time of prognosis of relapse is usually recommended Ev